Project Grant R21AI180397
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$449K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $504,703 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Georgia Research Foundation, Inc. The grant aims to further optimize and integrate a novel ultra-sensitive PCR (UltraPCR) method for detecting and quantifying Trypanosoma cruzi, the parasite that causes Chagas disease. The goal is to develop this UltraPCR platform as a confirmatory diagnostic test and to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,969 Project Grant to L2 Diagnostics LLC under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to evaluate a mosquito salivary protein, AGBR1, as a potential vaccine candidate against Chikungunya virus, an arboviral disease transmitted by infected mosquitoes. The project aims to conduct comparative assessments of different AGBR1 vaccine formulations, including...
This $144,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to investigate the immunologic mechanisms underlying the development of Chagas cardiomyopathy, a debilitating heart condition that affects 30-40% of individuals infected with Trypanosoma cruzi. The research will use advanced techniques like single-cell RNA sequencing and spatial transcriptomics to characterize the immune cell...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $561,538 to Abwiz Bio Inc. to develop neutralizing antibodies against Machupo virus, a New World arenavirus. The goal is to utilize advanced immunization techniques, a stabilized antigen, and high-throughput screening to identify and characterize antibodies that target multiple epitopes on the viral surface...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $843,620 to the Albert Einstein College of Medicine to develop broadly inhibitory antibody therapies against arthritogenic and encephalitic alphaviruses. The research aims to: 1) engineer Fc mutations into broadly protective antibodies to enhance their in vitro and in vivo properties, 2) perform viral escape studies to...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover the targets of naturally acquired protection against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The award, totaling $708,202 and effective from December 2024 through November 2029, will support research at Brown University to identify the parasite...
The federal Project Grant award of $700,288 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to identify genetic factors associated with the development of sexual stages (gametocytes) in the malaria parasite Plasmodium falciparum. The project combines expertise in gametocyte biology, advanced computational genomics, and phenotype comparisons with clinical...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $355,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Georgia Southern University Research & Service Foundation Inc. The grant will support research to develop comprehensive morphological and molecular identification tools for Hyalomma tick species that are vectors of Crimean-Congo Hemorrhagic Fever virus. The project aims to resolve the systematics of closely related...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $209,750 to Emory University to leverage antibody-omics to prevent and detect tuberculosis (TB) in children affected by HIV. The overarching goals are to define antibody Fc features associated with protection from Mycobacterium tuberculosis (MTB) infection among HIV-exposed infants (Aim 1) and identify biomarkers...
This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...